BioSpace News Archive

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the initiation of Phase 2 clinical trials evaluating the safety and efficacy of ADX‑629, a novel, internally developed, investigational oral RASP modulator, for the treatment of minimal change disease and Sjögren-Larsson Syndrome.

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its fourth quarter and full-year 2022 financial results and operational highlights in a conference call on February 23, 2023, at 8 a.m. ET.

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2022 financial results after U.S. financial markets close on Thursday, February 23, 2023.

Pasithea Therapeutics Corp. announced that Prof. Lawrence Steinman, Pasithea’s Chairman and National Academy of Sciences Professor, will receive the 2023 Pioneer in Medicine Award at the 20th Annual Gathering for the Cure on February 17 as part of the 20th Annual World Congress of SBMT.

Trevi Therapeutics, Inc. announced senior leadership will be presenting at the virtual Emerging Growth Conference on Wednesday, February 22, at 10:50 a.m. ET.

Bluejay Diagnostics, Inc., and Blood Centers of America announced that they have executed a collaborative agreement to develop commercial relationships to serve unmet needs by utilizing the SymphonyTM Platform in the blood and hospital markets.

ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that the Company will release its fourth quarter and fiscal year-end 2022 financial results on Thursday, February 23, 2023, at 8:30 AM Eastern time.

Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, today presented its Phase 2 clinical trial in progress of lead therapeutic candidate, PT-112, in patients with late-stage metastatic castration-resistant prostate cancer (mCRPC).

Mallinckrodt plc, a global specialty pharmaceutical company, announced that Siggi Olafsson, President and Chief Executive Officer, will present at Cowen’s 43rd Annual Health Care Conference in Boston, MA on Tuesday, March 7, 2023 at 2:50 p.m. Eastern Time.

Akamis Bio today announced an expansion of its ongoing partnership with the Parker Institute for Cancer Immunotherapy (PICI) to include a clinical collaboration with the Cancer Research Institute (CRI) that will focus on advancing novel treatments for pancreatic cancer.